Latest News and Press Releases
Want to stay updated on the latest news?
-
SEATTLE, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
-
SEATTLE, July 30, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
-
SEATTLE, July 16, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
-
SEATTLE, July 11, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
-
SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
-
SEATTLE, June 06, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
-
SEATTLE, May 17, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases,...
-
SEATTLE, May 15, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases,...
-
SEATTLE, April 23, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics Inc. (Nohla), a clinical stage biopharmaceutical company focused on the development of universal, off-the-shelf cell therapies to treat...
-
SEATTLE and PHILADELPHIA, March 21, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal donor cell therapies for patients with hematologic malignances and other critical...